target audience: TECH BUYER  Publication date: Nov 2022 - Document type: IDC MarketScape - Doc  Document number: # US48061722

IDC MarketScape: Worldwide Life Science R&D Risk-Based Monitoring Solutions 2022 Vendor Assessment

By:  Nimita Limaye Loading


Get More

When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.

Related Links


This IDC study focuses on a combination of RBM technology and consulting solutions. This IDC MarketScape provides a qualitative and quantitative assessment based on criteria that should be important to life science companies when considering the selection of a strategic RBM solution provider to help provide guidance for strategic, operational, and tactical transformation issues within the RBM-RBQM space, as well as technology platforms, and build capabilities. This is the first time that an IDC MarketScape assessment of RBM solutions for life science R&D has been performed.

Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology at IDC, noted, "The differentiator for great enterprises is not the amount of data that they have but the intelligence that they extract from it to minimize study risk, enhance data quality, and drive patient safety. The future of intelligence for clinical trials encompasses effectively leveraging an RBQM strategy, deeply embedding a QbD approach within the organization's DNA, building a quality-centric culture, and optimizing the use of technology solutions to develop an agile, predictive, prescriptive, and a proactive strategy to managing risks."


Do you have questions about this document
or available subscriptions?